Analysis Indraprastha Medical Corporation Limited (INDRAMEDCO)
6/1/2024
Analysis of Indraprastha Medical Corporation Limited (INDRAMEDCO)
Indraprastha Medical Corporation Limited (INDRAMEDCO) has shown some fluctuations in its stock price recently. The Relative Strength Index (RSI) values have been hovering around the mid-range, indicating a balanced market sentiment without any extreme overbought or oversold conditions.The Moving Average Convergence Divergence (MACD) indicator has been negative, suggesting a bearish trend in the short term. The MACD histogram has been decreasing, indicating a weakening bearish momentum.
The Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) have been relatively close to each other, indicating a stable trend in the stock price.
Overall, the stock of Indraprastha Medical Corporation Limited seems to be trading in a range-bound pattern with no clear directional bias at the moment. Traders and investors may need to closely monitor the price movements and key technical indicators for potential trading opportunities.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuations metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price summary shows the stock's performance over the past year, with details on beta, moving averages, and the 52-week range.
Valuations metrics reveal the company's valuation multiples, such as P/E ratio, PEG ratio, price to book, price to sales, and enterprise value multiples. The market capitalization is also provided.
Lastly, dividends and splits information includes details on dividend rates, payout ratio, dividend dates, and historical split information.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous year.
4. For the next year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the previous year.
Overall, the analysts' estimates show a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. It indicates a steady but slightly slower growth trajectory in the future.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the past four fiscal years.
2. The EBIT (Earnings Before Interest and Taxes) has also shown a positive trend, indicating efficient operational performance.
3. The Gross Profit margin has been relatively stable, suggesting effective cost management.
4. Net Income has been growing consistently, reflecting overall profitability.
5. Diluted EPS (Earnings Per Share) has shown a slight fluctuation but remains at a healthy level.
6. The company has been able to maintain a stable number of outstanding shares over the years.
7. Overall, the financial performance of the company, in terms of revenue generation and profitability, appears to be strong and improving.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown a positive trend, indicating a healthy financial position.
6. The company has been investing in non-current assets, possibly for long-term growth and sustainability.
7. There is a consistent level of short-term debt and accounts payable, which the company manages within its current assets.
8. The company has been retaining earnings and maintaining a stable level of common stock.
9. Overall, the financial health of the company seems robust, with a good balance between assets, liabilities, and equity.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant changes each year, with large amounts being spent on common stock repurchase and debt issuance.
6. Investing activities also vary, with notable amounts spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, but there are fluctuations in different areas that may require further analysis.
MACD of INDRAMEDCO
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
